S&P 500
7,357.80
-0.44%
Dow Jones
51,945.60
-0.47%
Nasdaq 100
29,082.80
-1.56%
Russell 2000
3,005.17
-0.36%
FTSE 100
10,505.10
-0.38%
Nikkei 225
69,696.60
-2.22%
Organon

OGN Q4 2025 Earnings

Reported Feb 12, 2026 at 7:45 AM ET · SEC Source

Q4 25 EPS

$0.63

MISS 13.34%

Est. $0.73

Q4 25 Revenue

$1.51B

MISS 0.51%

Est. $1.51B

vs S&P Since Q4 25

+88.2%

BEATING MARKET

OGN +95.2% vs S&P +6.9%

Full Year 2025 Results

FY 25 EPS

$3.66

MISS 2.62%

Est. $3.76

FY 25 Revenue

$6.22B

MISS 0.13%

Est. $6.22B

Market Reaction

Did OGN Beat Earnings? Q4 2025 Results

Organon closed out 2025 on a difficult note, with fourth-quarter results falling short on both the top and bottom lines as a $301 million non-cash goodwill impairment charge tied to underperforming U.S. Products dominated the headline story. Adjusted… Read more Organon closed out 2025 on a difficult note, with fourth-quarter results falling short on both the top and bottom lines as a $301 million non-cash goodwill impairment charge tied to underperforming U.S. Products dominated the headline story. Adjusted EPS came in at $0.63, missing the $0.76 consensus estimate by 17.11%, while revenue of $1.51 billion edged just below the $1.52 billion consensus and declined 5.3% year over year. The impairment swung Q4 to a GAAP net loss of $205 million, against net income of $109 million a year earlier. Women's Health, the company's flagship franchise, bore considerable weight as Nexplanon revenue dropped 20% on a constant-currency basis, pressured by U.S. Policy-related access restrictions and roughly $17 million in lost wholesaler sales. Biosimilars offered a rare bright spot, growing 11% on the strength of Hadlima and newly launched assets. Looking ahead, Organon guided for approximately $6.20 billion in 2026 revenue and roughly $1.90 billion in adjusted EBITDA, both essentially flat with 2025, while a recently announced licensing deal for a hormone-free copper IUD signals continued investment in rebuilding its women's health portfolio.

Key Takeaways

  • • Hadlima drove strong biosimilars growth
  • • Emgality and Vtama contributed to Established Brands revenue
  • • U.S. policy-related access restrictions negatively impacted Nexplanon sales
  • • Cessation of certain U.S. wholesaler sales practices reduced Nexplanon by approximately $17 million
  • • Pricing pressure and foreign exchange adversely affected gross margins
  • • Respiratory portfolio declined due to pricing pressure and adoption of revised medical guidelines deprioritizing montelukast
  • • Non-cash goodwill impairment of $301 million related to U.S. product underperformance
  • • One-time manufacturing and supply network optimization costs compressed reported gross margin

OGN Forward Guidance & Outlook

For full year 2026, Organon expects revenue of approximately $6.2 billion and Adjusted EBITDA of approximately $1.9 billion, both in-line with 2025 performance. The company expects the annual revenue foregone from the JADA system divestiture to be approximately offset by favorable currency translation, resulting in constant currency revenue growth about flat with prior year pro forma for the divestiture. Adjusted gross margin is expected to be 75-100 basis points lower than 2025. SG&A is expected in the mid-20% range, R&D in the mid-single digit range. Interest expense is expected at approximately $500 million. The effective non-GAAP tax rate is expected to be 27.5%-29.5%, up from 24.4% in 2025. Fully diluted weighted average shares are expected at approximately 265 million.

24/7 Wall St

OGN YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

24/7 Wall St

OGN Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q4 25
24/7 Wall St

OGN Revenue by Geography

With YoY comparisons, source: SEC Filings

Q1 25 Q4 25

“In 2025 we took action that demonstrated our commitment to improving the balance sheet and to building more financial flexibility.”

— Joe Morrissey, Q4 2025 Earnings Press Release

Back to OGN Stock Page